Fiches pratiques thérapeutiques pour la prise en charge des patients atteints de sclérose en plaques

Leray, 2010, Evidence for a two-stage disability progression in multiple sclerosis, Brain J Neurol, 133, 1900, 10.1093/brain/awq076 Brown, 2019, Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis, JAMA, 321, 175, 10.1001/jama.2018.20588 Harding, 2019, Clinical outcomes of escalation vs early intensive disease-modifying therapy in patients with multiple sclerosis, JAMA Neurol, 76, 536, 10.1001/jamaneurol.2018.4905 Spelman, 2021, Treatment escalation vs immediate initiation of highly effective treatment for patients with relapsing-remitting multiple sclerosis: data from 2 different national strategies, JAMA Neurol, 78, 1197, 10.1001/jamaneurol.2021.2738 Lublin, 2014, Defining the clinical course of multiple sclerosis: the 2013 revisions, Neurology, 83, 278, 10.1212/WNL.0000000000000560 Brisset, 2020, New OFSEP recommendations for MRI assessment of multiple sclerosis patients: Special consideration for gadolinium deposition and frequent acquisitions, J Neuroradiol J Neuroradiol, 47, 250, 10.1016/j.neurad.2020.01.083 Wattjes, 2021, 2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis, Lancet Neurol, 20, 653, 10.1016/S1474-4422(21)00095-8 Plavina, 2014, Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy, Ann Neurol, 76, 802, 10.1002/ana.24286 Cohen, 2019, Late-onset neutropenia following ocrelizumab therapy for multiple sclerosis, Neurology, 92, 435, 10.1212/WNL.0000000000006924 Zanetta, 2020, Late onset absolute neutropenia associated with ocrelizumab treatment in multiple sclerosis: a case report and review of the literature, J Neurol Sci, 409, 116603, 10.1016/j.jns.2019.116603 Marrodan, 2021, Rituximab- and ocrelizumab-induced early- and late-onset neutropenia in a multiple sclerosis patient, Neurol Sci Off, 42, 3893, 10.1007/s10072-021-05357-1 Lebrun, 2019, Immunization and multiple sclerosis: recommendations from the French Multiple Sclerosis Society, Rev Neurol (Paris), 175, 341, 10.1016/j.neurol.2019.04.001 Papeix, 2021, Infections and multiple sclerosis: recommendations from the French Multiple Sclerosis Society, Rev Neurol (Paris), 177, 980, 10.1016/j.neurol.2021.04.011 Bigaut, 2021, How to switch disease-modifying treatments in multiple sclerosis: guidelines from the French Multiple Sclerosis Society (SFSEP), Mult Scler Relat Disord, 53, 103076, 10.1016/j.msard.2021.103076